1910 Genetics

What is 1910 Genetics?

1910 Genetics is a next-generation biotechnology firm that combines computational modeling, biological automation, and proprietary data streams to streamline the discovery of both small and large molecule therapeutics. Its platform integrates computational simulations, proxy biological data from sequencing, and ground truth biological assays within an automated lab environment, enabling rapid design, synthesis, and testing of novel drug candidates. The company targets a broad range of diseases including neurological, autoimmune, infectious diseases, and cancer, significantly reducing development timelines and costs compared to traditional methods.

Key Features

• Multimodal Data Integration

  Combines computational, proxy biological, and ground truth biological data to enhance drug candidate design and validation.

• Automated Laboratory Platform

  Robotics-driven wet lab automation enables high-throughput synthesis and testing, accelerating iterative drug development cycles.

• Small and Large Molecule Discovery

  Supports design and optimization of both traditional small molecules and large biologics across diverse therapeutic targets.

• Therapeutic Area Agnostic

  Applicable to multiple disease areas including neuroscience, autoimmune disorders, infectious diseases, and oncology.

• Proprietary AI-Enabled Drug Design Engines

  Uses advanced AI platforms like BAGEL and SUEDE to generate and screen novel drug candidates rapidly.

Use Cases

• Accelerated Drug Lead Discovery : Pharmaceutical companies can shorten timelines from concept to lead compound using integrated AI and automation.
• Non-Opioid Pain Therapeutics : Development of novel small molecule candidates targeting non-opioid pathways for chronic pain management.
• Infectious Disease Drug Development : Rapid identification and validation of antiviral candidates, demonstrated by SARS-CoV-2 entry inhibitors.
• Partnering with Pharma and Research Institutions : Offers co-discovery, co-engineering, and platform-as-a-service models to accelerate partner R&D productivity.

FAQs